Valognes

Researchers are evaluating whether giving amiodarone for 72 hours can reduce the risk of death or severe dangerous heart rhythms in critically ill patients admitted after an out-of-hospital cardiac arrest with a shockable heart rhythm and a confirmed or suspected cardiac cause. This phase 3 study focuses on improving outcomes within 30 days after treatment starts, addressing a critical period following cardiac arrest where complications are common. Participants receive an initial 300 mg loading dose of amiodarone over 30 minutes in a glucose solution, followed by a continuous infusion for 72 hours at a dose of 10 mg/kg per day, not exceeding 900 mg in 24 hours. The treatment is given through a central venous catheter in the intensive care unit. The study compares this preventive approach to standard care to see if it lowers the chance of death or severe ventricular arrhythmias requiring urgent intervention. During the study, participants are closely monitored in the ICU with regular assessments to track heart rhythms and overall health status. Researchers measure the rate of mortality and severe ventricular arrhythmias within 30 days from the start of treatment. Safety and treatment effects are carefully observed during this critical period to determine if prophylactic amiodarone can improve patient outcomes after cardiac arrest.